BioSpace News Archive

Kyowa Kirin Co., Ltd. announced that disease education and data from the Phase 2b study of rocatinlimab, an investigational product being studied in patients with moderate-to-severe atopic dermatitis, will be presented at the upcoming American Academy of Dermatology 2024 Annual Meeting in San Diego from March 8-12, 2024.

MiNK Therapeutics, Inc. (NASDAQ: INKT) today announced the first patient dosed in a Phase 2 investigator sponsored study for agenT-797 in second line gastroesophageal cancer, led by Dr. Yelena Janjigian at Memorial Sloan Kettering Cancer Center.

IN8bio, Inc. today announced a publication in Frontiers in Immunology that reviews IN8bio’s novel approach for solid tumors, such as glioblastoma (GBM), an aggressive form of brain cancer.

YS Biopharma Co., Ltd. today announced that the Company received a requisition to convene an extraordinary general meeting (“EGM”) of the Company (the “Requisition”) from APEX Prospect Limited (the “Requisitioning Shareholder”), a registered member of the Company that holds no less than 10% of the aggregate voting power of the Company’s share capital as of February 12, 2024.

Elsie Biotechnologies, Inc. announced today that GSK plc (LSE/NYSE: GSK) has exercised its option to a non-exclusive license to Elsie’s discovery platform, following a successful outcome of the research collaboration, announced in July 2023, to explore the platform capabilities.

ProJenX, a clinical-stage biotechnology company developing novel, brain-penetrant therapies targeting biologically-defined pathways for the treatment of amyotrophic lateral sclerosis (ALS) and other debilitating brain diseases, today announced that it has received authorization in the European Union (EU) for study PRO-101, a hybrid Phase 1 clinical trial evaluating prosetin—a first-in-class MAP4K inhibitor—in healthy volunteers and participants with ALS.

Establishment Labs Holdings Inc. plans to announce its financial results for the quarter ended December 31, 2023, after the market closes on Wednesday, February 28, 2024, and will host a conference call at 4:30 pm ET that day to discuss those results.

Biotricity Inc. provided selected preliminary financial results for its fiscal third quarter 2024 results, ended December 31, 2023, that include record gross margins and record operational efficiency.

TheracosBio today announced that it is extending its collaboration with the Mark Cuban Cost Plus Drug Company.

Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX ® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility Study.